Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

(2014) H Eda et al.   LEUKEMIA

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor

(2014) W Guo et al.   Cell Death & Disease

Lipid biology of breast cancer

(2013) Jan Baumann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss

(2013) Masahiro Shinohara et al.   BONE

Cellular Fatty Acid Metabolism and Cancer

(2013) Erin Currie et al.   Cell Metabolism

A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis

(2013) Cheryl Eifert et al.   GENES CHROMOSOMES & CANCER

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)

(2013) Jan A. Burger et al.   LEUKEMIA & LYMPHOMA

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia

(2012) S. G. Landt et al.   GENOME RESEARCH

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

(2012) Joseph J. Buggy et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Current management and novel agents for malignant melanoma

(2012) Byung Lee et al.   Journal of Hematology & Oncology

Glycoprotein transmembrane nmb: An androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells

(2012) Ke-Hung Tsui et al.   PROSTATE

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

More than just B-cell inhibition

(2011) Eric M Ruderman et al.   ARTHRITIS RESEARCH & THERAPY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

Spatial Patterns of Localized-Stage Prostate Cancer Incidence Among White and Black Men in the Southeastern United States, 1999-2001

(2010) S. F. Altekruse et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

(2010) Julie A Di Paolo et al.   Nature Chemical Biology

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation

(2008) Seoung Hoon Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone

(2008) K. Chu et al.   MOLECULAR CANCER RESEARCH

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

(2008) Da Wei Huang et al.   NUCLEIC ACIDS RESEARCH